David Conn, Chief Commercial Officer, Glooko

David Conn, Chief Commercial Officer, Glooko

David Conn 300px.jpg

Dave Conn is Chief Commercial Officer at Glooko, a digital health company focused on improving the lives of people with diabetes by using data and technology to create and deliver actionable insights. With 30 years of experience in the healthcare industry, Dave has held a variety of leadership positions in companies ranging from startups to Fortune 100s. His areas of expertise include strategic deal negotiations, acquisition and integration, organizational development and business process management. Dave holds a BA in Marketing and Management from Ashland University.

Casper de Clercq, General Partner, Norwest Venture Partners

Casper de Clercq, General Partner, Norwest Venture Partners

Casper-de-clercq-banner-28-10-2.jpg

With over 30 years of experience, Casper is a veteran of the medical device and life sciences industry, having led marketing and commercialization efforts for companies that span the healthcare space. He brings extensive operating knowledge to Norwest Venture Partners, where he focuses on mid-to-late-stage investments in consumer and digital health, healthcare IT, medical devices and diagnostics, technology-enabled healthcare services, and specialty pharmaceuticals. He currently serves on the boards of Omada Health, NextHealth Technologies, and Science Exchange. Casper was previously on the board of Basis (acquired by Intel), Crossover Health (acquired by Gurnet Point Capital), Intersect ENT (Nasdaq: XENT), iRhythm Technologies (Nasdaq: IRTC) and Telcare (acquired by BioTelemetry). Casper is also responsible for Norwest’s investment in Misfit Wearables (acquired by Fossil).

Prior to Norwest, Casper was a Partner at U.S. Venture Partners (USVP) in Menlo Park, where he invested in therapeutic companies from clinical development through commercialization. At USVP, Casper served as a Board member for AtheroMed, Ilypsa (acquired by Amgen) and Valeritas. Over a six year period he was actively involved in making and managing investments in more than a dozen companies as a member of the healthcare team. Casper was also a private investor and board member with Innospine, an orthopedic diagnostic company acquired by Kyphon in 2005.

Previously, Casper spent four years as Vice President of Business Development, Sales and Marketing at Aerogen, a specialty pharmaceutical company developing inhaled therapeutics for diabetes and respiratory diseases (public company acquired by Nektar then Novartis). In 1999 he co-founded and venture funded Epicor to develop a market leading epicardial ablation treatment for atrial fibrillation (acquired by St. Jude Medical for over $200M in 2004).

Prior to Epicor, Casper held senior marketing positions at Heartport (acquired by Johnson and Johnson) and Diagnostic Products Corporation (acquired by Siemens). At Heartport, Casper launched an integrated surgical product line to perform minimally invasive cardiovascular surgery. Previously at Diagnostics Products Corporation, he managed a portfolio of oncology, infectious disease and infertility immunoassay tests which doubled to $105M in revenues during his tenure. At these companies, Casper worked closely with the engineering, scientific and clinical teams in product development, coordinated multiple U.S. product launches and had ongoing responsibility for managing international distribution.

Earlier in his career, Casper worked internationally for three years as a strategy consultant for Bain & Company.

Casper holds an M.B.A. from Stanford University Graduate School of Business, an M.S. in biological science from Stanford University and a B.A. in biochemistry from Dartmouth College.

Sean Duffy, Co-Founder and CEO, Omada Health

Sean Duffy, Co-Founder and CEO, Omada Health

SeanDuffy_2018_new.jpg

Sean Duffy is the Co-founder and CEO of Omada Health, a digital behavioral medicine company dedicated to inspiring and empowering people everywhere to live free of obesity-related chronic conditions like heart disease and type 2 diabetes. In 2017, Omada was recognized as one of Fast Company’s World's Most Innovative Companies and in 2016, the company was named a Technology Pioneer by the World Economic Forum.

Sean’s past speaking engagements include the World Economic Forum annual conference, Clinton Global Initiative Health Matters Summit, the Society for Behavioral Medicine, the JPMorgan Healthcare Conference, and others. He has written extensively about digital health and the future of healthcare in The New England Journal of Medicine, The Wall Street Journal, Forbes, and TechCrunch, among other publications.

Prior to Omada, Sean worked at both Google and IDEO. A former MD/MBA candidate at Harvard, he holds a BS in neuroscience from Columbia University.

Andrew ElBardissi, MD, Investor, Private Transaction team, Deerfield Management

Andrew ElBardissi, MD, Investor, Private Transaction team, Deerfield Management

Andrew ElBardissi Headshot.jpg

Dr. Andrew ElBardissi is an investor on the Private Transaction team at Deerfield Management. Prior to joining Deerfield, Dr. ElBardissi held roles as an early stage life-sciences investor and as an Investment Banker at J.P. Morgan’s Healthcare practice. Dr. ElBardissi holds an M.D. from the Mayo Clinic, an M.P.H. in Quantitative Methods from Harvard University, an M.B.A. from Harvard Business School. He received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. Dr. ElBardissi has been independently funded by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ), has over 30 publications in leading peer reviewed scientific journals, and has presented his research at numerous medical and surgical conferences.

Dr. ElBardissi’s board memberships include Acutus, Farapulse, SentreHeart, Sollis Therapeutics, vWave, Conventus, Neochord, Incarda Therapeutics, Epic Sciences, and Cathworks.

John Groetelaars, President & CEO, Hill-Rom

John Groetelaars, President & CEO, Hill-Rom

Groetelaars-8x10HR for web.jpg

John P. Groetelaars joined Hill-Rom Holdings, Inc., as president and chief executive officer in May 2018. Previously, Mr. Groetelaars was executive vice president and president of Becton, Dickinson and Company’s (BD) Interventional Segment, where his responsibilities included global strategic, operational and commercial performance, and delivering the segment’s financial performance and innovation platform. Prior to the BD acquisition of C.R. Bard, Mr. Groetelaars was group president at Bard, which he had joined in 2008. He previously held positions of increasing responsibility with Boston Scientific Corporation, Guidant Corporation and Eli Lilly. Mr. Groetelaars earned his bachelor’s degree in Mechanical Engineering from Kettering University in Michigan, and an MBA from Columbia University in New York.

Marie Johnson, PhD, Founder & CEO, AUM Cardiovascular

Marie Johnson, Founder & CEO, AUM Cardiovascular

Marie_Johnson_AUM_Cardiovascular_Medsider.jpg

Dr. Marie Johnson is CEO and President of AUM Cardiovascular, Inc., a Northfield, Minnesota based medical device company developing game-changing wireless diagnostic devices for detecting coronary obstructive blockage.  Dr. Johnson has 25 years of experience in product development and manufacturing in both Fortune 500 companies and university environments.  Prior to founding AUM Cardiovascular, she created and led the University of Minnesota Medical Device Innovation Fellowship, modeled after the Stanford biodesign program.  Dr. Johnson holds a BS in Mechanical Engineering, a MS and PhD in Biomedical Engineering and has completed three post-doctoral fellowships.  Dr. Johnson has patents and patents pending in the United States, Europe, China, India and Taiwan in a broad range of disciplines including orthopedic, cardiovascular, ob/gyn, automotive and food safety.  Dr. Johnson holds an adjunct faculty position and holds the medical device emphasis advisor position in Biomedical Engineering department at the University of Minnesota.

Tippi MacKenzie, Professor of Surgery, UCSF, & Co-Director, UCSF Center for Maternal-Fetal Precision Medicine

Tippi MacKenzie, Professor of Surgery, UCSF, & Co-Director, UCSF Center for Maternal-Fetal Precision Medicine

TCM headshot 2018.jpg

Tippi MacKenzie is a pediatric and fetal surgeon who is focused on developing better ways to diagnose and treat genetic diseases before birth. She runs a translational research lab examining the unique biology between the mother and her fetus, with the idea that pregnancy complications such as preterm labor arise from a breakdown in maternal-fetal tolerance. She is the Principal Investigator on the world’s first Phase 1 clinical trial to perform in utero hematopoietic stem cell transplantation to treat fetuses with alpha thalassemia. Her research has been supported by the National Institutes of Health, the March of Dimes, the California Institute for Regeneration Medicine, and the Burroughs-Wellcome Fund. Tippi has been awarded the Jacobson Award by the American College of Surgeons for her innovative work.

Tippi trained in classical piano at Juilliard before obtaining her undergraduate degree from Harvard College and her medical degree from Stanford University. She completed her surgical residency at Brigham and Women’s Hospital in Boston and obtained additional fellowships in Fetal Surgery and Pediatric Surgery at the Children’s Hospital of Philadelphia. She joined the faculty at the University of California, San Francisco in 2007 and is now a Professor of Surgery. In addition to her clinical practice, she is also a member of the Eli and Edythe Broad Institute for Regeneration Medicine and the Biomedical Sciences Program. She recently co-founded the Center for Maternal-Fetal Precision Medicine, with the aim of accelerating the processes that link basic research to clinical trials to improve maternal, fetal, and neonatal health. This Center is testing methods to improve prenatal diagnosis of birth defects and developing new cellular and molecular therapies for definitive fetal treatment.

Harith Rajagopalan, MD, PhD, Co-Founder and CEO, Fractyl

Harith Rajagopalan, MD, PhD, Co-Founder and CEO, Fractyl

harith-rajagopalan-fractyl*750xx3648-4864-0-0.jpg

Harith Rajagopalan, M.D., Ph.D., is Co-founder and CEO of Fractyl, having started the company while serving as an Entrepreneur-in-Residence at General Catalyst Partners.

Prior to founding Fractyl, Harith was an academic cardiologist and physician-scientist. He received his B.S. in chemistry from Stanford University and went on to obtain M.D. and Ph.D. degrees from Johns Hopkins School of Medicine. At Johns Hopkins, Harith did groundbreaking and award-winning research on intestinal cancers that was published in top medical journals, including Nature and Science.

After medical school, Harith trained in internal medicine and clinical cardiology at Brigham and Women’s Hospital and completed a research fellowship at the Harvard Stem Cell Institute at Harvard Medical School.

Stanton J. Rowe, CEO, NXT Biomedical

Stanton J. Rowe, CEO, NXT Biomedical

rowe.jpg

Stanton J. Rowe is CEO of NXT Biomedical, a medical device incubator funded by Deerfield Capital. Stanton recently retired from Edwards Lifesciences where he was Chief Scientific Officer since 2008 and also served as Corporate Vice President, Advanced Technology. He joined in 2004 when Edwards acquired Percutaneous Valve Technologies, a company he helped to found in 1999 and served as President and CEO.

This company developed the first transcatheter aortic valve replacement. Previously, Rowe was Corporate Vice President for Datascope and was Vice President at Johnson & Johnson’s Interventional Systems Division (JJIS) in Warren, New Jersey, responsible for the company’s coronary stent development efforts. At JJIS and the related Cordis Corporation, Rowe held a variety of positions with increasing levels of responsibility, including heading the company’s business development, advanced technology, worldwide clinical research and marketing groups. Rowe joined Cordis after previously holding several positions in product management for a number of medical device companies.

He is on the board of directors of both InSeal Medical, Ltd., NeuralAnalytics, PQ Bypass. He is also on the Board of Directors for the Discovery Science Center in Orange County, Sage Hill School, as well as on the advisory boards for the engineering, business school, and biomedical engineering schools at UC Irvine. Rowe received a bachelor’s degree from the University of Alabama.

Ruchita Sinha, Senior Director of Investments, Sanofi Ventures

Ruchita Sinha, Senior Director of Investments, Sanofi Ventures

ruchita.jpg

Ruchita joined Sanofi Ventures in 2016 with a relevant background in digital health. Prior to Sanofi, Ruchita was at GE Ventures, where she invested in and built partnerships with healthcare startups and served as a board observer for several portfolio companies. Ruchita also managed GE’s seed-stage portfolio of digital health investments in partnership with StartUp Health.

Ruchita has more than 15 years of healthcare experience in pharma, biotech, medical devices, and healthcare IT. Prior to GE Ventures, Ruchita was at Pfizer’s Strategy, BD, & Portfolio Management group, and a management consultant with LEK Consulting. Ruchita started her career with Maxygen, an early stage biotech company.

Ruchita is currently a board observer for Inozyme and Omada Health.

Ruchita holds an MBA from the University of Chicago, an MS in Cellular and Molecular Biology from the University of Wisconsin-Madison, and a BS in Biochemistry from Mount Holyoke College.

Christine Winoto, Director, Rosenman Institute; Founding Partner, MedTech Venture Partners

Christine Winoto, Director, Rosenman Institute; Founding Partner, MedTech Venture Partners

_OR_1915.jpg

Christine Winoto is Director of the Rosenman Institute, Deputy Director of QB3, and Founding Partner at MedTech Venture Partners I, LLP. Christine manages the Rosenman Institute, Biotech/Biopharma Pitch Summits, corporate partnership, and QB3 operations. She is also host of the Health Technology podcast. Before joining QB3, she managed business strategy and capital planning for Kaiser Permanente both on the hospital and health plan sides, and managed business development at Genencor. In addition to consulting for startups and venture capital, she has also held R&D and operations positions in medical device companies including Physiometrix (IPO, then acquired by Hospira), Cardiovasc and Heartport. Christine also worked in mergers and acquisitions at the London office of the Dutch investment bank ABN AMRO. Christine holds an MBA from Erasmus University in the Netherlands.